http://www.jcps.ac.cn

Journal of Chinese Pharmaceutical Sciences ›› 2015, Vol. 24 ›› Issue (1): 12-27.DOI: 10.5246/jcps.2015.01.002

• Original articles • Previous Articles     Next Articles

Elucidation of regulatory interaction networks underlying human prostate adenocarcinoma

Sujit Nair1,2, Celine Liew3, Tin-Oo Khor2, Li Cai4, Ah-Ng Tony Kong2*   

  1. 1. Amrita Cancer Discovery Biology Laboratory and Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham University, Ponekkara P.O., Kochi-682041, Kerala, India
    2. Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ-08854, USA
    3. Department of Pharmacy, National University of Singapore, 18, Science Drive 4, Singapore-117543
    4. Department of Biomedical Engineering, Rutgers, the State University of New Jersey, Piscataway, NJ-08854, USA 
  • Received:2014-09-26 Revised:2014-11-14 Online:2015-01-15 Published:2014-11-15
  • Contact: Tel.: +848-445-6369/8, Fax: +732-445-3134
  • Supported by:
    RO1 CA 094828 to Prof. Ah-Ng Tony Kong and in part by R21 CA133675 to Dr. Li Cai both from the National Institutes of Health (NIH).

Abstract:

The incidence of prostate cancer is rising in the Asia-Pacific region as well as other countries. Androgen-ablation therapy is clinically useful in the androgen-dependent phenotype; however, many patients progress to hormone refractory prostate cancer that is difficult to treat and needs newer interventions that are more effective. The objective of this study was to determine functionally-relevant biological networks, to appreciate the potential crosstalk between signaling members, and to identify biomarker signatures in prostate cancer. We used microarray analyses to identify key genes that were upregulated or down regulated at least five-fold in human prostate cancer and constructed canonical interaction networks that are important in prostate cancer through metabolomics analyses. Our prostate cancer network architecture revealed several key biomarkers including ERK1/2, JNK, p38, MEK, PI3K, NFκB, AP-1, 14-3-3, VEGF, PDGF, Rb, WNT8A, WNT10A, CD44, ESR2, FSH and LH. Furthermore, the top ten transcription factors identified by TFBS-association signature analysis in the regulatory elements of co-regulated biomarkers were delineated, which may crosstalk with upstream or downstream genes elicited in our network architecture. Taken together, our results demonstrate that the regulatory interaction networks in prostate cancer provide a universal view of crosstalk between important biomarkers, i.e., key players in the pathogenesis of this disease. This will facilitate more rapid screening of functional biomarkers in early/intermediate drug discovery.

Key words: Human prostate cancer, Microarray, Biological network, Biomarker

CLC Number: 

Supporting: